Journal Information
Vol. 35. Issue 2.
Pages 94-96 (February 1999)
Vol. 35. Issue 2.
Pages 94-96 (February 1999)
Full text access
Tratamiento actual del carcinoma broncopulmonar no microcítico y nueva clasificación TNM
Visits
3266
J. Sánchez de Cos Escuín*
Unidad de Neumología. Hospital San Pedro de Alcántara. Cáceres
This item has received
Article information
Full text is only aviable in PDF
Bibliografía
[1.]
Grupo de Trabajo, SEPAR..
Normativa actualizada (1998) sobre diagnóstico y estadificación del carcinoma broncogénico, 34 (1998), pp. 437-452
[2.]
C.F. Mountain.
Revisions in the “International System for Staging Lung Cancer”.
Chest, 111 (1997), pp. 1.710-1.717
[3.]
Grupo Cooperativo de Carcinoma Broncogénico de la, SEPAR..
Reflections on the revisions in the International System for Staging Lung Cancer.
Chest, (1998), pp. 113
[4.]
American Thoracic Society/European Respiratory, Society.
Pretreatment evaluation of non-small cell lung cancer.
Am J Respir Crit Care Med, 156 (1997), pp. 320-332
[5.]
American Society of Clinical, Oncology.
Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer.
J Clin Oncol, 15 (1997), pp. 2.996-3.018
[6.]
D.J. Mathisen.
Surgical therapy for stage IIIA non-small cell lung cancer. Educational Book.
ASCO, (1998), pp. 290-293
[7.]
P.A. Bunn, K. Kelly.
Systemic investigational therapies as adjuvants to surgery in patients with operable lung cancer.
Semin Oncol, 24 (1997), pp. 46-52
[8.]
T.A.W. Splinter.
Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer.
Semin Oncol, 23 (1996), pp. 659-661
[9.]
D.A. Johnson.
Adjuvant chemotherapy for non-small cell lung cancer.
Lung Cáncer, 17 (1997), pp. 103-110
[10.]
J.C. Ruckdeschel, H. Wagner, L.A. Robinson.
Locally advanced lung cancer: controversies in management. Advances in oncology.
ASCO, (1996), pp. 12
[11.]
U. Pastorino.
Benefits of neoadjuvant chemotherapy in NSCLC.
Chest, 109 (1996), pp. 96-101
[12.]
W. Eberhardt, H. Wilke, G. Stamatis, M. Stuschke, H. Hartrick, G. Menker, et al.
Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a phase II trial.
J Clin Oncol, 16 (1998), pp. 622-634
[13.]
R. Rossell, J. Gómez Codina, A. Camps, J. Maestre, J. Padilla, A. Cantó, et al.
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer.
N Engl J Med, 330 (1994), pp. 153-158
[14.]
J.A. Roth, F. Fossella, R. Komaki.
A randomized trial comparing perioperative chemotherapy plus surgery alone in resectable stage IIIA non-small cell lung cancer.
J Natl Cancer Inst, 86 (1994), pp. 673-680
[15.]
ThJ. Lynch.
Treatment of stage III non-small cell lung cancer. Educational Book.
ASCO, (1998), pp. 265-275
[16.]
C. Belani, R. Ramanathan.
Combined modality treatment of locally advanced non-small cell lung cancer. Incorporation of novel chemotherapeutic agents.
Chest, 113 (1998), pp. 53-60
[17.]
C. Belani.
Paclitaxel/carboplatin/radiotherapy. US experience. Pan-European interactive forum. New perspectives on the management of lung cancer.
Sitges (Barcelona), marzo de, (1998),
[18.]
W.T. Sause, M. Machtay.
Treatment of non-small cell lung cancer: Radiation therapy.
Pulmonary diseases and disorders, 3. a, pp. 1.805-1.818
[19.]
Non-Small Cell Lung Cancer Coliaborative, Group.
Chemotherapy in non-small cell lung cancer: a meta-analysis using up-dated data on Individual patients from 52 randomized clinical triáis, 311 (1995), pp. 899-909
[20.]
B. Jeremic, Y. Shibamato, L. Acimovic, L. Milisavljevic.
Hyperfractionated radiation therapy with or without concurrent low-dose carboplatinetoposide for stage III non-small cell lung cancer. A randomized study.
J Clin Oncol, 14 (1996), pp. 1.065-1.070
[21.]
N.C. Choi.
Management of stage III non-small cell lung cancer: progress in preoperative chemorradiotherapy. Educational Book.
ASCO, (1998), pp. 276-289
[22.]
R. Ginsberg, J. Cox, M. Creen, H. Bulzebruck, D. Grunewald, P. Harper, et al.
Staging classification committee.
Consensus report. Lung Cancer, 17 (1997), pp. 11-13
[23.]
K. Albain, V.W. Rusch, J.J. Crowley, T. Rice, A.T. Turrisi, J.K. Weick, et al.
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest oncology group. Phase II study (8805).
J Clin Oncol, 13 (1995), pp. 1.880-1.892
[24.]
J. Treat.
Treatment of non-small cell lung cancer: chemotherapy.
Pulmonary diseases and disorders, 3. a ed., pp. 1.709-1.804
[25.]
J.J. Albain, A.T. Crowley, A.T. Turrisi, D.R. Gándara, W.B. Farrar, J. Clark, et al.
Concurrent cisplatin/etoposide plus radiotherapy for pathologic stage IIIB non-small cell lung cancer: a Southwest oncology group. Phase II study (S9019) (Denver: ASCO, May 1720, 1997).
J Clin Oncol, 16 (1997), pp. 446
[26.]
E.C. Holmes.
Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferenciated carcinoma.
Chest, 106 (1994), pp. 293-296
[27.]
T. Lad.
The comparison of CAP chemotherapy and radiotherapy to radiotherapy alone for resected lung cancer with positive margin or involved highest sampled paratracheal node (stage IIIA). LCSG 791.
Chest, 106 (1994), pp. 302-306
[28.]
M. Ohta, R. Tsuchiya, M. Shimoyama, K. Sawamura, T. Mori, N. Miyazawa, et al.
Adjuvant chemotherapy for completeley resected stage III non-small cell lung cancer. Results of a randomized prospective study.
J Thorac Cardiovasc Surg, 106 (1993), pp. 703-708
[29.]
H. Wada, S. Hitomi, T. Teramatsu.
Adjuvant chemotherapy after complete resection in non-small cell lung cancer.
J Clin Oncol, 14 (1996), pp. 1.048-1.054
Copyright © 1999. Sociedad Española de Neumología y Cirugía Torácica